AI Engines For more Details: Perplexity Kagi Labs You
Blood Pressure Control: Telmisartan helps to lower blood pressure by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict. By dilating blood vessels, telmisartan reduces resistance to blood flow, thus lowering blood pressure.
Hypertension Management: Telmisartan is indicated for the management of hypertension, either as monotherapy or in combination with other antihypertensive medications. It is effective in reducing both systolic and diastolic blood pressure.
Cardiovascular Protection: Telmisartan has been shown to provide cardiovascular protection by reducing the risk of cardiovascular events such as heart attack, stroke, and heart failure in patients with hypertension or other cardiovascular risk factors.
Renoprotective Effects: Telmisartan may help protect the kidneys in patients with hypertension and diabetic nephropathy (kidney disease caused by diabetes). It can slow the progression of kidney damage and reduce proteinuria (excess protein in the urine).
Diabetic Complications: Telmisartan is beneficial in patients with type 2 diabetes mellitus, as it can help prevent or delay the onset of diabetic complications such as diabetic nephropathy and cardiovascular disease.
Heart Failure: Telmisartan is sometimes used in the management of heart failure with reduced ejection fraction (HFrEF) to improve symptoms and reduce the risk of hospitalization for heart failure exacerbations.
Tolerability: Telmisartan is generally well-tolerated, with a low incidence of adverse effects. Common side effects may include dizziness, headache, fatigue, and upper respiratory tract infections. These side effects are usually mild and transient.
Dual Therapy: Telmisartan is available in combination with other antihypertensive agents, such as hydrochlorothiazide, to provide additive blood pressure-lowering effects. This combination therapy may improve treatment adherence and simplify medication regimens.
Once-Daily Dosage: Telmisartan is typically administered once daily, which enhances convenience and adherence to treatment compared to medications that require multiple daily doses.
Contraindications: Telmisartan is contraindicated in patients with a history of hypersensitivity to the drug or other ARBs, as well as in pregnant women due to the risk of fetal harm. It should be used with caution in patients with renal impairment or bilateral renal artery stenosis.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
ADHD | 2.3 | 0.7 | 2.29 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | 0 |
Allergic Rhinitis (Hay Fever) | 1.8 | 1.8 | |
Allergies | 3.3 | 1.3 | 1.54 |
Allergy to milk products | 1.3 | 0.8 | 0.63 |
Alopecia (Hair Loss) | 1.3 | 1.3 | |
Alzheimer's disease | 2.6 | 5.4 | -1.08 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.6 | 1.67 |
Ankylosing spondylitis | 3.4 | 0.8 | 3.25 |
Anorexia Nervosa | 0.5 | 2 | -3 |
Antiphospholipid syndrome (APS) | 2.8 | 0.2 | 13 |
Asthma | 1 | 0.8 | 0.25 |
Atherosclerosis | 0.2 | 2 | -9 |
Atrial fibrillation | 2.5 | 2 | 0.25 |
Autism | 8.4 | 6.9 | 0.22 |
Barrett esophagus cancer | 0.2 | 0.5 | -1.5 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 1.3 | 1.2 | 0.08 |
Brain Trauma | 0.8 | -0.8 | |
Carcinoma | 2.3 | 1.1 | 1.09 |
Celiac Disease | 2.2 | 1.3 | 0.69 |
Cerebral Palsy | 1 | 1.1 | -0.1 |
Chronic Fatigue Syndrome | 3.2 | 5.6 | -0.75 |
Chronic Kidney Disease | 2.2 | 1.8 | 0.22 |
Chronic Lyme | 0.8 | -0.8 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.6 | 1 | 1.6 |
Chronic Urticaria (Hives) | 1.8 | 1.6 | 0.13 |
Coagulation / Micro clot triggering bacteria | 1.8 | 1.3 | 0.38 |
Colorectal Cancer | 4.6 | 0.4 | 10.5 |
Constipation | 1.4 | 0.8 | 0.75 |
Coronary artery disease | 0.7 | 0.8 | -0.14 |
COVID-19 | 7.6 | 10.2 | -0.34 |
Crohn's Disease | 6.3 | 4 | 0.57 |
cystic fibrosis | 0.9 | 0.8 | 0.13 |
deep vein thrombosis | 0.9 | 1 | -0.11 |
Depression | 7.9 | 6.5 | 0.22 |
Dermatomyositis | 0.5 | 0.5 | |
Eczema | 0.6 | 2.8 | -3.67 |
Endometriosis | 2.9 | 2.9 | |
Eosinophilic Esophagitis | 0.2 | 0.2 | |
Epilepsy | 2.4 | 1.9 | 0.26 |
Fibromyalgia | 3.4 | 3.2 | 0.06 |
Functional constipation / chronic idiopathic constipation | 4.8 | 4.2 | 0.14 |
gallstone disease (gsd) | 1.6 | 0.7 | 1.29 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 1.1 | 0.82 |
Generalized anxiety disorder | 1.7 | 1.3 | 0.31 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 0.7 | 0.8 | -0.14 |
Halitosis | 0.5 | 0.5 | 0 |
Hashimoto's thyroiditis | 1.8 | 0.5 | 2.6 |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 1 | 1.2 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 0.3 | 1.1 | -2.67 |
hypersomnia | 0.6 | -0.6 | |
hypertension (High Blood Pressure | 1.5 | 3.2 | -1.13 |
Hypothyroidism | 1.1 | -1.1 | |
Hypoxia | 0.7 | 0.7 | |
IgA nephropathy (IgAN) | 3 | -3 | |
Inflammatory Bowel Disease | 4.7 | 7 | -0.49 |
Insomnia | 1.1 | 0.8 | 0.38 |
Intelligence | 1.7 | 0.8 | 1.13 |
Intracranial aneurysms | 1.1 | 1.1 | |
Irritable Bowel Syndrome | 3 | 2.8 | 0.07 |
Liver Cirrhosis | 3.8 | 2.5 | 0.52 |
Long COVID | 6.6 | 4.3 | 0.53 |
Low bone mineral density | 1 | -1 | |
Lung Cancer | 0.4 | 0.3 | 0.33 |
ME/CFS with IBS | 1.1 | 1.9 | -0.73 |
ME/CFS without IBS | 2.1 | 1.3 | 0.62 |
Metabolic Syndrome | 5.9 | 5.9 | 0 |
Mood Disorders | 9.6 | 6.7 | 0.43 |
multiple chemical sensitivity [MCS] | 1.5 | 0.3 | 4 |
Multiple Sclerosis | 4.4 | 6.7 | -0.52 |
Multiple system atrophy (MSA) | 1 | 0.3 | 2.33 |
Neuropathy (all types) | 0.8 | 0.3 | 1.67 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 2.6 | -0.13 |
Obesity | 4.6 | 2.7 | 0.7 |
obsessive-compulsive disorder | 6.2 | 3.2 | 0.94 |
Osteoarthritis | 2.6 | 2.6 | |
Osteoporosis | 1.3 | 0.6 | 1.17 |
pancreatic cancer | 0.5 | 0.5 | |
Parkinson's Disease | 2.5 | 4.6 | -0.84 |
Polycystic ovary syndrome | 2.7 | 1 | 1.7 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.5 | 0 |
Premenstrual dysphoric disorder | 0.3 | 0.5 | -0.67 |
primary biliary cholangitis | 0.7 | -0.7 | |
Psoriasis | 2.7 | 3.5 | -0.3 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.8 | 2.8 | 0.71 |
Rosacea | 0.7 | 1 | -0.43 |
Schizophrenia | 3.9 | 1.8 | 1.17 |
scoliosis | 0.5 | 0.2 | 1.5 |
Sjögren syndrome | 2.3 | 2.2 | 0.05 |
Sleep Apnea | 1 | 1.8 | -0.8 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 1.3 | |
Stress / posttraumatic stress disorder | 2.5 | 1.7 | 0.47 |
Systemic Lupus Erythematosus | 4.2 | 0.8 | 4.25 |
Tic Disorder | 0.9 | 0.8 | 0.13 |
Tourette syndrome | 0.3 | -0.3 | |
Type 1 Diabetes | 3.4 | 2.4 | 0.42 |
Type 2 Diabetes | 6.2 | 7 | -0.13 |
Ulcerative colitis | 2.4 | 4.8 | -1 |
Unhealthy Ageing | 6.2 | 1.8 | 2.44 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.